Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Questcor Collaborates on Novel Melanocortin Peptides

By R&D Editors | May 15, 2014

Questcor Pharmaceuticals Inc. announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen, this transaction significantly expands Questcor’s portfolio of melanocortin therapeutics and further establishes the company as the leader in this important emerging field of medicine.
 
“Our commercial experience and scientific evaluation of both Acthar and Synacthen has allowed us to develop a comprehensive understanding of the potential for melanocortin therapeutics in the treatment of serious autoimmune and inflammatory diseases,” said Steve Cartt, chief operating officer of Questcor. “We are particularly excited that this collaboration allows us to build on our success by investing in the development of the next generation of melanocortin therapeutics. Our efforts will focus on novel, receptor-selective peptide compounds designed to target specific melanocortin cellular receptors in order to address specific diseases with high unmet medical need. This effort has the potential to more effectively address certain diseases where the broader melanocortin pharmacological profiles of both Acthar and Synacthen are less desirable, including new indications for which neither product is presently utilized.”
 
The agreement includes a technology platform that provides Questcor with a novel library of melanocortin peptides. The company has already conducted initial preclinical evaluation on a number of peptides and from this exercise has selected lead peptides with which to move forward. Unlike Acthar and Synacthen, which are broad-acting melanocortin peptide formulations which bind to all five known melanocortin receptors, the licensed technology platform provides peptides designed to target specific melanocortin receptors that Questcor believes are particularly relevant to autoimmune and inflammatory diseases. Among other key characteristics, the peptides have been designed to minimize activation of the melanocortin 2 receptor in order to limit endogenous cortisol production and related steroid side effects. The company believes this technology platform has extensive and long term intellectual property protection. The company will initially focus on conducting formulation and manufacturing activities involving the lead peptides and performing additional preclinical research in order to match the lead peptides with lead indications for clinical development.
 
Under the terms of the collaboration, Questcor has secured an exclusive worldwide license to the peptides and technology. Questcor will fund the development of the peptides and will have the option to acquire the technology at a later date. 
 
Date: May 14, 2014
Source: Questcor Pharmaceuticals

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE